Immune reconstitution
| Lymphocyte subset . | Time point post-ASCT* . | |||||
|---|---|---|---|---|---|---|
| BL, 0-45 d post-ASCT . | 2 mo . | 3 mo . | 6 mo . | 12 mo . | 18 mo . | |
| Effector T cells (CD3+CD8+) | ||||||
| Study patients† | 362.4 | 378.5 | 421.7 | 389.4 | 380.9 | 248.3 |
| Controls† | 260.4 | 372.5 | 196.5 | 189.2 | 222.8 | 250.8 |
| P | .16 | .41 | .056 | .11 | .37 | .37 |
| Helper T cells (CD3+CD4+) | ||||||
| Study patients† | 200.1 | 217.5 | 196.6 | 193.9 | 227.9 | 288.5 |
| Controls† | 290.4 | 267.6 | 181.4 | 222 | 288.5 | 319.3 |
| P | .16 | .49 | .31 | .62 | .22 | .63 |
| Regulatory T cells (CD4+CD25+CD127−) | ||||||
| Study patients† | 24.6 | 26.6 | 19.5 | 18.6 | 19.1 | 27.2 |
| Controls† | 35 | 11.1 | 14.3 | 11.7 | 17.6 | 21.5 |
| P | .52 | .078 | .15 | .036 | .87 | .16 |
| NK cells (CD3−CD56+) | ||||||
| Study patients† | 260.1 | 192 | 148.6 | 152.7 | 97.8 | 130.5 |
| Controls† | 199.4 | 169.2 | 89.7 | 71.2 | 117.4 | 110.5 |
| P | .081 | .82 | .026 | .026 | .84 | .82 |
| B cells (CD19+) | ||||||
| Study patients† | 7.8 | 131.4 | 155.1 | 190.9 | 275.1 | 269.9 |
| Controls† | 3 | 143.9 | 32.3 | 207.5 | 297.2 | 201.3 |
| P | .12 | .49 | .022 | .73 | .7 | .94 |
| Lymphocyte subset . | Time point post-ASCT* . | |||||
|---|---|---|---|---|---|---|
| BL, 0-45 d post-ASCT . | 2 mo . | 3 mo . | 6 mo . | 12 mo . | 18 mo . | |
| Effector T cells (CD3+CD8+) | ||||||
| Study patients† | 362.4 | 378.5 | 421.7 | 389.4 | 380.9 | 248.3 |
| Controls† | 260.4 | 372.5 | 196.5 | 189.2 | 222.8 | 250.8 |
| P | .16 | .41 | .056 | .11 | .37 | .37 |
| Helper T cells (CD3+CD4+) | ||||||
| Study patients† | 200.1 | 217.5 | 196.6 | 193.9 | 227.9 | 288.5 |
| Controls† | 290.4 | 267.6 | 181.4 | 222 | 288.5 | 319.3 |
| P | .16 | .49 | .31 | .62 | .22 | .63 |
| Regulatory T cells (CD4+CD25+CD127−) | ||||||
| Study patients† | 24.6 | 26.6 | 19.5 | 18.6 | 19.1 | 27.2 |
| Controls† | 35 | 11.1 | 14.3 | 11.7 | 17.6 | 21.5 |
| P | .52 | .078 | .15 | .036 | .87 | .16 |
| NK cells (CD3−CD56+) | ||||||
| Study patients† | 260.1 | 192 | 148.6 | 152.7 | 97.8 | 130.5 |
| Controls† | 199.4 | 169.2 | 89.7 | 71.2 | 117.4 | 110.5 |
| P | .081 | .82 | .026 | .026 | .84 | .82 |
| B cells (CD19+) | ||||||
| Study patients† | 7.8 | 131.4 | 155.1 | 190.9 | 275.1 | 269.9 |
| Controls† | 3 | 143.9 | 32.3 | 207.5 | 297.2 | 201.3 |
| P | .12 | .49 | .022 | .73 | .7 | .94 |
Median absolute numbers of selected lymphocyte subsets are shown post-ASCT and compared between study patients (N = 30; treated with pembrolizumab) and control patients (N = 30; no pembrolizumab) (see “Methods” for details). The significance level was set as 0.01 to account for multiplicity of testing.
Samples drawn outside of the given time points are grouped with the closest specified time point (see “Methods”). Not all patients had available samples at all time points.
Median of absolute numbers, in cells ×106/L.